Patents by Inventor Munekazu Kanda
Munekazu Kanda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160273016Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: May 27, 2016Publication date: September 22, 2016Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi UEDA, Yoko WATAMOTO, Masaru TSUBOI, Munekazu KANDA, Tomoji HIGAKI, Mitsunori MATSUDA
-
Patent number: 9371361Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: GrantFiled: April 21, 2015Date of Patent: June 21, 2016Assignee: ASTELLAS PHARMA INC.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20150225453Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: April 21, 2015Publication date: August 13, 2015Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi UEDA, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Patent number: 8445634Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: GrantFiled: May 17, 2012Date of Patent: May 21, 2013Assignee: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Patent number: 8426556Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: GrantFiled: May 17, 2012Date of Patent: April 23, 2013Assignee: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20120225830Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: May 17, 2012Publication date: September 6, 2012Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi UEDA, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20120225829Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: May 17, 2012Publication date: September 6, 2012Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi UEDA, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Patent number: 7611724Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.Type: GrantFiled: March 3, 2009Date of Patent: November 3, 2009Assignee: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Patent number: 7608280Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.Type: GrantFiled: March 17, 2008Date of Patent: October 27, 2009Assignee: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20090264343Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: June 30, 2009Publication date: October 22, 2009Applicant: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20090264617Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: June 30, 2009Publication date: October 22, 2009Applicant: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20090156785Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: March 3, 2009Publication date: June 18, 2009Applicant: Astellas Pharma Inc.Inventors: Satoshi UEDA, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20080227975Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: March 17, 2008Publication date: September 18, 2008Applicant: Astellas Pharma Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Patent number: 7396665Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant.Type: GrantFiled: August 22, 2001Date of Patent: July 8, 2008Assignee: Astellas Pharma, Inc.Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda
-
Publication number: 20030186388Abstract: Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.Type: ApplicationFiled: February 27, 2003Publication date: October 2, 2003Inventors: Satoshi Ueda, Yoko Watamoto, Masaru Tsuboi, Munekazu Kanda, Tomoji Higaki, Mitsunori Matsuda